Abstract
Seventy-one allograft recipients receiving voriconazole, in whom complete clinical, microbiologic and pharmacokinetic data were available, were studied to determine the efficacy of voriconazole in preventing fungal infections. The length of voriconazole therapy was 6–956 days (median 133). The total number of patient-days on voriconazole was 13 805 (∼38 years). A total of 10 fungal infections were seen in patients on voriconazole (18% actuarial probability at 1 year): Candida glabrata (n=5), Candida krusei (n=1), Cunninghamella (n=1), Rhizopus (n=2) and Mucor (n=1). Two of the four zygomycosis cases were preceded by short durations of voriconazole therapy, but prolonged itraconazole prophylaxis. The plasma steady-state trough voriconazole levels around the time the infection occurred were <0.2, <0.2, 0.33, 0.55, 0.63 and 1.78 μg/ml in the six candidiasis cases. Excluding the four zygomycosis cases, all the six candidiasis cases were seen among the 43 patients with voriconazole levels of ⩽2 μg/ml and none among the 24 with levels of >2 μg/ml (P=0.061). We conclude that voriconazole is effective at preventing aspergillosis. However, breakthrough zygomycosis is seen in a small proportion of patients. The role of therapeutic voriconazole monitoring with dose adjustment to avoid breakthrough infections with fungi that are otherwise susceptible to the drug needs to be explored prospectively.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Nucci M, Marr KA . Emerging fungal infections. Clin Infect Dis 2005; 41: 521–526.
Singh N, Paterson DL . Aspergillus Infections in transplant patients. Clin Microbiol Rev 2005; 18: 44–69.
Sullivan KM, Dykewicz CA, Longworth DL, Boeckh M, Baden LR, Rubin RH et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: The Centers for Disease Control, Infectious Disease Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology (Am Soc Hematol Educ Program) 2001, 392–421.
Trifilio SM, Verma A, Mehta J . Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant 2004; 33: 735–739.
Andes D, Forrest A, Lepak A, Nett J, Marchillo K, Lincoln L . Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob Agents Chemother 2006; 50: 2374–2383.
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415.
Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrobiol Agents Chemother 2003; 47: 3149–3154.
Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225–234.
Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570–1572.
Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527–1533.
Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35: 509–513.
Pennick GJ, Clark M, Sutton DA, Rinaldi MG . Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 2003; 47: 2348–2350.
Siwek GT, Pfaller MA, Polgreen PM, Cobb S, Hoth P, Magalheas-Silverman M et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis 2006; 55: 209–212.
Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055–2061.
Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634–653.
Kontoyiannis DP, Lewis RE . Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am 2006; 20: 581–607.
Marty FM, Cosimi LA, Baden LR . Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950–952.
Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case–control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350–1360.
Verma A, Williams S, Trifilio S, Zembower T, Mehta J . Successful treatment of concomitant pulmonary zygomycosis and aspergillosis with a combination of amphotericin B lipid complex, caspofungin, and voriconazole in a patient on immunosuppression for chronic graft-versus-host disease. Bone Marrow Transplant 2004; 33: 1065–1066.
Marr KA, Seidel K, White TC, Bowden RA . Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309–316.
www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_02_FDA-voriconazole.htm (Accessed 9 November 2006; page search term ‘Voriconazole Efficacy Response Assessment’).
Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44: 819–826.
Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De Beule K . Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989; 32 (Suppl 1): 103–108.
Berenguer J, Ali NM, Allende MC, Lee J, Garrett K, Battaglia S et al. Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother 1994; 38: 1303–1308.
Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E, Losem C et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42: 443–451.
Acknowledgements
No financial support was received for this work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Trifilio, S., Singhal, S., Williams, S. et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 40, 451–456 (2007). https://doi.org/10.1038/sj.bmt.1705754
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705754
Keywords
This article is cited by
-
Breakthrough Invasive Sinusitis by Hormographiella aspergillata in a Neutropenic Patient Receiving Voriconazole Therapy: A Case Report and Review of Breakthrough H. aspergillata Infections
Mycopathologia (2023)
-
High incidence of resistant breakthrough invasive fungal infections (IFD) in patients treated for acute gastrointestinal graft-versus-host disease (GI GVHD) following allogeneic haematopoietic cell transplantation
Bone Marrow Transplantation (2022)
-
Multicenter Registry of Patients Receiving Systemic Mold-Active Triazoles for the Management of Invasive Fungal Infections
Infectious Diseases and Therapy (2022)
-
A phase I dose finding study of intravenous voriconazole in pediatric patients undergoing hematopoietic cell transplantation
Bone Marrow Transplantation (2020)
-
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Intensive Care Medicine (2020)